Boston Scientific Corporation (NYSE:BSX) has been assigned an average recommendation of “Buy” from the twenty-one ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $30.39.

A number of research firms have recently commented on BSX. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific Corporation in a research report on Tuesday, October 3rd. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $34.00 target price on shares of Boston Scientific Corporation in a research note on Monday, October 2nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $32.00 target price on shares of Boston Scientific Corporation in a research note on Monday, September 25th. Jefferies Group LLC reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a research note on Thursday, September 7th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $30.00 target price on shares of Boston Scientific Corporation in a research note on Wednesday, June 21st.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/11/boston-scientific-corporation-bsx-receives-consensus-recommendation-of-buy-from-analysts.html.

Shares of Boston Scientific Corporation (NYSE:BSX) traded down 0.31% during trading on Wednesday, hitting $29.25. 916,028 shares of the stock traded hands. The stock has a 50-day moving average of $28.44 and a 200 day moving average of $27.10. The company has a market cap of $40.13 billion, a P/E ratio of 52.23 and a beta of 1.09. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.54.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period last year, the business earned $0.27 earnings per share. Boston Scientific Corporation’s revenue was up 6.2% compared to the same quarter last year. On average, equities research analysts predict that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

In other Boston Scientific Corporation news, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $27.13, for a total transaction of $420,515.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Supratim Bose sold 347,137 shares of Boston Scientific Corporation stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $29.12, for a total transaction of $10,108,629.44. The disclosure for this sale can be found here. Insiders have sold 531,297 shares of company stock worth $15,144,095 over the last three months. Insiders own 0.74% of the company’s stock.

Several hedge funds have recently bought and sold shares of the business. Lord Abbett & CO. LLC purchased a new position in shares of Boston Scientific Corporation during the second quarter worth approximately $40,460,000. Sentry Investment Management LLC raised its stake in shares of Boston Scientific Corporation by 1.1% during the second quarter. Sentry Investment Management LLC now owns 107,243 shares of the medical equipment provider’s stock worth $2,973,000 after acquiring an additional 1,125 shares in the last quarter. WFG Advisors LP raised its stake in shares of Boston Scientific Corporation by 17.3% during the second quarter. WFG Advisors LP now owns 157,919 shares of the medical equipment provider’s stock worth $4,378,000 after acquiring an additional 23,305 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of Boston Scientific Corporation by 26.1% during the second quarter. Toronto Dominion Bank now owns 463,826 shares of the medical equipment provider’s stock worth $12,854,000 after acquiring an additional 95,902 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd raised its stake in shares of Boston Scientific Corporation by 80.8% during the second quarter. Dynamic Technology Lab Private Ltd now owns 16,800 shares of the medical equipment provider’s stock worth $466,000 after acquiring an additional 7,507 shares in the last quarter. 90.44% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.